Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M42,330Revenue (TTM) $M4,649Net Margin (%)15.7Altman Z-Score14.1
Enterprise Value $M41,647EPS (TTM) $6.3Operating Margin %26.8Piotroski F-Score6
P/E(ttm)63.8Beneish M-Score-2.7Pre-tax Margin (%)26.7Higher ROA y-yY
Price/Book10.410-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsY
Price/Sales10.05-y EBITDA Growth Rate %--Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow44.3y-y EBITDA Growth Rate %24.2ROA % (ttm)13.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)20.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M105ROIC % (ttm)23.4Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNJoel Greenblatt 2016-06-30 Add0.12%$331.05 - $427.2
($384.74)
$ 402.024%Add 1094.10%30,151
REGNVanguard Health Care Fund 2016-06-30 Add0.08%$331.05 - $427.2
($384.74)
$ 402.024%Add 3.46%3,279,190
REGNMario Gabelli 2016-06-30 Reduce$331.05 - $427.2
($384.74)
$ 402.024%Reduce -1.04%1,329
REGNRon Baron 2016-06-30 Reduce$331.05 - $427.2
($384.74)
$ 402.024%Reduce -0.48%4,987
REGNVanguard Health Care Fund 2016-03-31 Add0.71%$359.68 - $542.87
($414.39)
$ 402.02-3%Add 38.98%3,169,490
REGNRon Baron 2016-03-31 Reduce-0.01%$359.68 - $542.87
($414.39)
$ 402.02-3%Reduce -32.86%5,011
REGNJoel Greenblatt 2016-03-31 Reduce-0.01%$359.68 - $542.87
($414.39)
$ 402.02-3%Reduce -39.26%2,525
REGNMario Gabelli 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 402.02-3%Reduce -2.54%1,343
REGNKen Fisher 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 402.02-3%Reduce -0.33%613
REGNVanguard Health Care Fund 2015-12-31 Reduce-0.17%$459.82 - $587.09
($543.11)
$ 402.02-26%Reduce -6.84%2,280,494
REGNJoel Greenblatt 2015-12-31 Buy 0.02%$459.82 - $587.09
($543.11)
$ 402.02-26%New holding4,157
REGNKen Fisher 2015-12-31 Add$459.82 - $587.09
($542.9)
$ 402.02-26%Add 22.02%615
REGNMario Gabelli 2015-12-31 Reduce$459.82 - $587.09
($543.11)
$ 402.02-26%Reduce -35.76%1,378
REGNVanguard Health Care Fund 2015-09-30 Reduce-0.32%$451.82 - $592.4
($537.03)
$ 402.02-25%Reduce -11.45%2,447,894
REGNRon Baron 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 402.02-25%Reduce -0.21%7,463
REGNKen Fisher 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 402.02-25%Reduce -10.80%504
REGNVanguard Health Care Fund 2015-06-30 Reduce-0.15%$438.27 - $539.4
($487.44)
$ 402.02-18%Reduce -5.36%2,764,540
REGNKen Fisher 2015-06-30 Add$438.27 - $539.4
($487.44)
$ 402.02-18%Add 5.81%565
REGNMario Gabelli 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 402.02-18%Reduce -2.05%2,145
REGNRon Baron 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 402.02-18%Reduce -0.15%7,479
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GOLDSTEIN JOSEPH LDirector 2016-07-29Sell2,125$425-5.41view
Sanofi10% Owner 2016-06-14Buy64,731$363.8610.49view
RYAN ARTHUR FDirector 2016-05-24Sell1,000$396.641.36view
Van Plew Daniel PEVP & General Mgr Industrial O 2016-05-18Sell4,413$385.774.21view
GOLDSTEIN JOSEPH LDirector 2016-04-06Sell2,000$425-5.41view
GOLDSTEIN JOSEPH LDirector 2016-03-21Sell2,000$3757.21view
Sanofi10% Owner 2016-02-17Buy161,157$392.462.44view
Sanofi10% Owner 2016-01-12Buy83,938$465.04-13.55view
McCorkle Douglas SVP Controller and Asst Treasur 2015-12-29Sell3,954$552.08-27.18view
BROWN MICHAEL SDirector 2015-12-10Sell3,000$546.45-26.43view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions Aug 14 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals Nov 23 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 

More From Other Websites
Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data... Oct 01 2016
Regeneron eczema drug reduces itch and anxiety, two studies show Oct 01 2016
Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data... Oct 01 2016
[$$] Regeneron Bulls Should Keep Eye on the Prize Sep 30 2016
Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone Sep 30 2016
What Will Gilead Try Buying Next? Polls Offer Some 'Incyte' Sep 30 2016
Chardan Rates Regeneron A Sell, Advises Caution Sep 30 2016
What Do Analysts Say about Regeneron’s Upside Potential? Sep 30 2016
Why RBS, Cheniere Energy, Regeneron Pharmaceuticals & Two Other Stocks Are in Spotlight Today Sep 30 2016
Regeneron Is a Late Entrant in Immuno-Oncology Space Sep 30 2016
Regeneron's Eylea combination therapy fails mid-stage study Sep 30 2016
Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta)... Sep 30 2016
7:01 am Regeneron Pharma announces the phase 2 study of aflibercept co-formulated with rinucumab... Sep 30 2016
Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta)... Sep 30 2016
Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure Sep 29 2016
Why Teva and Regeneron Entered Collaboration Agreement Sep 29 2016
How Regeneron Is Working to Maintain Eylea’s Dominance Sep 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)